- Home
- SERA
as 02-21-2025 4:00pm EST
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 208.7M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 148.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.84 - $12.36 | Next Earning Date: | 03-19-2025 |
| Revenue: | $94,000 | Revenue Growth: | -71.52% |
| Revenue Growth (this year): | -63.33% | Revenue Growth (next year): | 3081.82% |
Stock Insider Trading Activity of Sera Prognostics Inc. (SERA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kearney Paul | SERA | Chief Data Officer | Feb 12 '25 | Sell | $4.58 | 5,342 | $24,466.36 | 158,128 | |
| Jackson Benjamin | SERA | General Counsel | Feb 12 '25 | Sell | $4.58 | 5,915 | $27,090.70 | 106,239 | |
| Aerts Austin | SERA | Chief Financial Officer | Feb 12 '25 | Sell | $4.58 | 5,915 | $27,090.70 | 277,410 | |
| Jackson Benjamin | SERA | General Counsel | Jan 10 '25 | Sell | $7.00 | 29,591 | $201,133.27 | 106,239 | |
| Aerts Austin | SERA | Chief Financial Officer | Jan 10 '25 | Sell | $8.06 | 2,431 | $19,593.86 | 277,410 | |
| Phillips Joshua | SERA | Director | Jan 10 '25 | Sell | $6.97 | 34,211 | $230,468.54 | 4,229 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Jan 10 '25 | Sell | $7.26 | 16,473 | $119,678.05 | 116,837 | |
| Mirza Mansoor Raza | SERA | Director | Jan 6 '25 | Sell | $7.69 | 100 | $769.00 | 6,536 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Dec 10 '24 | Sell | $7.41 | 26,224 | $194,319.84 | 793,534 | |
| Aerts Austin | SERA | Chief Financial Officer | Dec 10 '24 | Sell | $7.41 | 5,730 | $42,459.30 | 277,410 |
Latest Sera Prognostics Inc. News
SERA Breaking Stock News: Dive into SERA Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
MT Newswires
11 days ago
Sera Prognostics Prices $50 Million Offering of Common Stock, Warrants
PR Newswire
12 days ago
Sera Prognostics Announces Pricing of $50 Million Public Offering
MT Newswires
12 days ago
Sera Prognostics Launches Equity Offering to Fund Expansion, Preterm Birth Risk Test Research
PR Newswire
12 days ago
Sera Prognostics Announces Proposed Public Offering
PR Newswire
a month ago
Sera Prognostics to Host Virtual R&D Day on January 31
PR Newswire
2 months ago
Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
2 months ago
With 40% stake, Sera Prognostics, Inc. (NASDAQ:SERA) seems to have captured institutional investors' interest
Compare SERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SERA Sera Prognostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.